Clifford Chance

Healthcare & Life Sciences Update: The Netherlands - November 2014

11 November 2014

The regulatory environment for companies active in the Dutch healthcare and life sciences sector continues to change. Rules regarding advertising have been amended and new supervision instruments are being introduced. On a European level, pharmacovigilance has been further harmonised, resulting in amendment of the Dutch Medicines Act. Pilots for funding of specific (more expensive) medicinal products are also being assessed and next steps are determined. This Healthcare & Life Sciences Update highlights certain recent developments in regulations and enforcement, which may impact your business.

Download PDF